Jasper Therapeutics Inc (NASDAQ: JSPR) has experienced a decline in its stock price by -12.26 compared to its previous closing price of 6.69. However, the company has seen a fall of -71.87% in its stock price over the last five trading days. globenewswire.com reported 2025-01-08 that Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile
Is It Worth Investing in Jasper Therapeutics Inc (NASDAQ: JSPR) Right Now?
The 36-month beta value for JSPR is at 2.26. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for JSPR is 11.24M, and currently, shorts hold a 20.62% of that float. The average trading volume for JSPR on January 15, 2025 was 440.10K shares.
JSPR’s Market Performance
JSPR’s stock has seen a -71.87% decrease for the week, with a -73.88% drop in the past month and a -60.89% fall in the past quarter. The volatility ratio for the week is 21.49%, and the volatility levels for the past 30 days are at 11.44% for Jasper Therapeutics Inc The simple moving average for the past 20 days is -67.84% for JSPR’s stock, with a -72.39% simple moving average for the past 200 days.
Analysts’ Opinion of JSPR
Many brokerage firms have already submitted their reports for JSPR stocks, with BMO Capital Markets repeating the rating for JSPR by listing it as a “Outperform.” The predicted price for JSPR in the upcoming period, according to BMO Capital Markets is $63 based on the research report published on December 06, 2024 of the previous year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see JSPR reach a price target of $70. The rating they have provided for JSPR stocks is “Mkt Outperform” according to the report published on September 09th, 2024.
BTIG Research gave a rating of “Buy” to JSPR, setting the target price at $90 in the report published on July 08th of the previous year.
JSPR Trading at -71.67% from the 50-Day Moving Average
After a stumble in the market that brought JSPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.07% of loss for the given period.
Volatility was left at 11.44%, however, over the last 30 days, the volatility rate increased by 21.49%, as shares sank -71.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.02% lower at present.
During the last 5 trading sessions, JSPR fell by -71.87%, which changed the moving average for the period of 200-days by -79.63% in comparison to the 20-day moving average, which settled at $18.25. In addition, Jasper Therapeutics Inc saw -72.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at JSPR starting from Mahal Jeetinder Singh, who sale 900 shares at the price of $22.11 back on Dec 12 ’24. After this action, Mahal Jeetinder Singh now owns 25,009 shares of Jasper Therapeutics Inc, valued at $19,899 using the latest closing price.
Jeetinder Singh Mahal, the Executive Officer of Jasper Therapeutics Inc, proposed sale 900 shares at $22.47 during a trade that took place back on Dec 12 ’24, which means that Jeetinder Singh Mahal is holding shares at $20,223 based on the most recent closing price.
Stock Fundamentals for JSPR
Current profitability levels for the company are sitting at:
- -33.47 for the present operating margin
- 0.58 for the gross margin
The net margin for Jasper Therapeutics Inc stands at -30.96. The total capital return value is set at -0.79. Equity return is now at value -71.46, with -60.56 for asset returns.
Based on Jasper Therapeutics Inc (JSPR), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -28.01.
Currently, EBITDA for the company is -64.98 million with net debt to EBITDA at 1.34. When we switch over and look at the enterprise to sales, we see a ratio of -1.16. The receivables turnover for the company is 8.21for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.61.
Conclusion
In conclusion, Jasper Therapeutics Inc (JSPR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
